AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14633528
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion analgesia (CEA) with ropivacaine 0.2%
Trial: 11104317
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (medication plus behavioral treatment)
Trial: 11104317
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment alone
Trial: 9116551
Drug: Prescription for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription for antibiotics for 10 days (group 1, 246 patients)
Trial: 9116551
Drug: No prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prescription (group 2, 230 patients)
Trial: 9116551
Drug: Prescription for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription for antibiotics if symptoms were not starting to settle after three days (group 3, 238 patients)
Trial: 30463611
Drug: cALND (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cALND (with chemotherapy)
Trial: 30463611
Drug: cALND (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cALND (before chemotherapy)
Trial: 30463611
Drug: cALND (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cALND (without chemotherapy)
Trial: 18755817
Drug: Talnetant 200
RxNorm normalized name: Talnetant
DrugBank: Talnetant (DB06429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talnetant 200 mg
Trial: 18487215
Drug: Oral pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentoxifylline (800 mg/day)
Trial: 12482765
Drug: Isoproterenol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol (20 and 40 ng.kg(‐1).min(‐1) for 15 min/dose)
Trial: 10683349
Drug: Mibefradil (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (initial 50 mg daily dose uptitrated to 100 mg after 1 month, continued up to 3 years)
Trial: 10683349
Drug: Placebo (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (as adjunct to usual therapy)
Trial: 9332510
Drug: Fluconazole 800
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 800 mg
Trial: 9332510
Drug: Prior antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior antifungal therapy failed
Trial: 9332510
Drug: Fluconazole (400-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400-800 mg)
Trial: 2944386
Drug: Acetaminophen, 1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, 1300 mg
Trial: 2944386
Drug: Meclofenamate, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate, 100 mg
Trial: 2944386
Drug: Meclofenamate, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate, 200 mg
Trial: 31421686
Drug: Viscosupplementation (VS)
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscosupplementation (VS) treatment
Trial: 24200619
Drug: FF/VI 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 100/25 mcg administered in the morning
Trial: 24200619
Drug: FF/VI 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 100/25 mcg administered in the evening
Trial: 24200619
Drug: FF/VI 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 100/25 mcg (morning or evening)
Trial: 22367374
Drug: Emollient cream
RxNorm normalized name: EMOLLIENT CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient cream containing 0.25% zinc pyrithione
Trial: 22367374
Drug: Emollient cream
RxNorm normalized name: EMOLLIENT CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient cream alone
Trial: 19780002
Drug: Rescue analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue analgesic (1 mg.kg(‐1) im meperidine)
Trial: 11318005
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (INO) at 1 part per million in the supine position
Trial: 11318005
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of INO and prone positioning
Trial: 8486508
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate as prophylactic migraine therapy
Trial: 22104390
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood injection added to standard treatment (eccentric-loading exercises) for 12 weeks
Trial: 22104390
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (eccentric-loading exercises) alone for 12 weeks
Trial: 20815273
Drug: Shenxiong Bushen
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenxiong Bushen Capsule (5 tablets, thrice a day)
Trial: 20815273
Drug: Piracetam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (5 tablets, twice a day)
Trial: 20815273
Drug: Shenxiong Bushen
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenxiong Bushen Capsule
Trial: 15804320
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument
Trial: 12445035
Drug: Omeprazole, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 120 mg day‐1 for 7 days
Trial: 7274202
Drug: Zinc ammonium
RxNorm normalized name: ammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc ammonium sulfate aerosol at a nominal concentration of 20 μg/m3
Trial: 7274202
Drug: Control: Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Sodium chloride aerosol at a nominal concentration of 300 μg/m3
Trial: 31186401
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no compound
Trial: 22695310
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg vaginal natural progesterone
Trial: 20064284
Drug: UMF 20+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMF 20+ honey (20 g)
Trial: 20064284
Drug: Multiflora honey
RxNorm normalized name: Reynoutria multiflora root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiflora honey (20 g)
Trial: 17378904
Drug: Iberogast (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberogast (1.1 mL)
Trial: 17378904
Drug: Control (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1.1 mL)
Trial: 12439764
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (c.c.HRT) with 1 mg estradiol plus 0.5 mg norethisterone acetate (NETA)
Trial: 7547823
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg elemental Calcium
Trial: 6996139
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of diazepam plus local anaesthetic spray
Trial: 30870159
Drug: Lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1 mg/kg bolus followed by continuous infusion (48 μg · kg · min for the first hour, 24 μg · kg · min for the second hour, and 10 μg · kg · min for the next 46 hours)
Trial: 25795741
Drug: Standard ground
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ground paramedic treatment
Trial: 15090392
Drug: Active low-energy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active low-energy extracorporeal shock wave treatment given weekly for 3 weeks
Trial: 15090392
Drug: Placebo extracorporeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo extracorporeal shock wave treatment (sham)
Trial: 9772598
Drug: Lappaconitine compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lappaconitine compound (12 mg lappaconitine and 22.5 mg bupivacaine)
Trial: 9772598
Drug: Lappaconitine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lappaconitine (12 mg) and bupivacaine (22.5 mg)
Trial: 30723735
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nutraceuticals containing 5 mg monacolin K, 200 mg Citrus bergamia, 400 mg Omega‐3, and 10 mcg trivalent chromium
Trial: 30723735
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nutraceuticals containing 3 mg monacolin K, 200 mg red yeast rice, 500 mg Berberine, 0.5 mg Astaxanthin, 200 mcg folic acid, 2 mg Coenzyme Q10, and 10 mg Policosanol
Trial: 22801191
Drug: Intradetrusor onabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intradetrusor onabotulinumtoxinA injections (300 IU)
Trial: 22801191
Drug: Suburothelial onabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Suburothelial onabotulinumtoxinA injections (300 IU)
Trial: 19241108
Drug: Aspirin (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (low dose)
Trial: 19241108
Drug: No tablets
RxNorm normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No tablets
Trial: 9849032
Drug: Chlamydia trachomatis
RxNorm normalized name: CHLAMYDIA TRACHOMATIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlamydia trachomatis antibodies
Trial: 9849032
Drug: N. gonorrhoeae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. gonorrhoeae antibodies
Trial: 9156955
Drug: Nifedipine SR
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine SR (20 mg, twice daily)
Trial: 18665761
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) 20 min a day with a 5‐mW soft laser for 6 months
Trial: 18665761
Drug: Betahistine 16
RxNorm normalized name: betahistine 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 16 mg twice a day for 6 months
Trial: 8441234
Drug: rhIGF-I, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-I, 60 micrograms/kg, subcutaneous injections, administered at 0800, 1400, and 2000 hours for 5.5 days
Trial: 28870129
Drug: Volar plating
RxNorm normalized name: platinic chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volar plating (surgical treatment)
Trial: 28870129
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (casting)
Trial: 25741871
Drug: PictureRx illustrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PictureRx illustrated medication list
Trial: 25741871
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (written list of medications in preferred language, with indication but no images)
Trial: 22237419
Drug: sifilcon A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sifilcon A penetrated hydrogel lenses (Dk/t ± 117) worn on a daily basis for 9 months
Trial: 20837741
Drug: Mandibular two-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular two-implant overdenture (OD)
Trial: 18498682
Drug: Chunghyul-dan 600
RxNorm normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chunghyul-dan 600 mg a day
Trial: 10081854
Drug: Transurethral resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral resection plus 100 mg. epirubicin
Trial: 7498868
Drug: 100 to
RxNorm normalized name: Zionodil 100 Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 to 120 mg of hypericum extract bid
Trial: 2206813
Drug: Ceftizoxime (intramuscular)
DrugBank: Ceftizoxime (DB01332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (intramuscular)
Trial: 2206813
Drug: Amoxycillin (oral)
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin (oral)
Trial: 7002569
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg/day by mouth, in three divided doses
Trial: 31066232
Drug: Sodium tanshinone
RxNorm normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium tanshinone IIA sulfonate (STS) 80 mg qd for 7 days
Trial: 30214156
Drug: Asenapine 1-10
RxNorm normalized name: asenapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 1-10 mg twice daily for up to 12 days
Trial: 30214156
Drug: Asenapine 2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 2.5-10 mg twice daily for up to 8 weeks
Trial: 27810972
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) - 2 doses (1 g/kg/dose)
Trial: 22290978
Drug: Asunaprevir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asunaprevir (200 to 600 mg twice daily)
Trial: 16250190
Drug: Augmented exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented exercise therapy time as Arm BASIS training (n=20)
Trial: 16250190
Drug: Augmented exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented exercise therapy time as Bobath therapy (n=20)
Trial: 16250190
Drug: No augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No augmented exercise therapy time (n=20)
Trial: 16250190
Drug: Augmented exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented exercise therapy time as Arm BASIS training
Trial: 16250190
Drug: Augmented exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented exercise therapy time as Bobath therapy
Trial: 11872999
Drug: Triple-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-drug regimen (ZDV + 3TC + IDV)
Trial: 11872999
Drug: Reinitiating either
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinitiating either the original triple-drug regimen or a new combination of nucleoside analogue reverse transcriptase inhibitors and protease inhibitors
Trial: 10666558
Drug: 11 mg
RxNorm normalized name: benzocaine 11 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 mg of midazolam
Trial: 10666558
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of scopolamine
Trial: 7834398
Drug: 300 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Trial: 7834398
Drug: 300 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms/kg rCD4‐IgG twice per week and 600 mg ZDV per day
Trial: 7834398
Drug: 1,000 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Trial: 7834398
Drug: 1,000 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 micrograms/kg rCD4‐IgG twice per week and 600 mg ZDV per day
Trial: 7834398
Drug: 3,000 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000 micrograms/kg rCD4‐IgG twice per week and 300 mg ZDV per day
Trial: 1964662
Drug: CY 216
RxNorm normalized name: Cys
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CY 216 (0.3 ml subcutaneous injections equivalent to 7,500 anti-Xa units)
Trial: 1964662
Drug: Placebo (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.3 ml saline solution)
Trial: 6155131
Drug: Pseudoephedrine 15
RxNorm normalized name: APAP 325/PSEUDOEPHEDRINE 15MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 15 mg
Trial: 6155131
Drug: Pseudoephedrine 30
RxNorm normalized name: pseudoephedrine 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 30 mg
Trial: 31958446
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg orally on day 1 and then 80 mg orally on days 2 to 7 with physician's choice of antitussive
Trial: 31958446
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice of antitussive alone
Trial: 29484635
Drug: Dipeptidyl Peptidase
RxNorm normalized name: Dipeptidyl peptidase I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipeptidyl Peptidase 1 Inhibitor AZD7986
Trial: 26465781
Drug: OCTREE (intraportal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCTREE (intraportal chemotherapy plus mFOLFOX6)
Trial: 26465781
Drug: mFOLFOX6 (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 (standard adjuvant chemotherapy)
Trial: 20557366
Drug: 14-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day quadruple therapy (Omeprazole 20 mg, Amoxicillin 1.0 g, Clarithromycin 500 mg, Bismuth Potassium Citrate 220 mg, twice a day)
Trial: 20557366
Drug: 7-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day quadruple therapy (Omeprazole 20 mg, Amoxicillin 1.0 g, Clarithromycin 500 mg, Bismuth Potassium Citrate 220 mg, twice a day)
Trial: 18447631
Drug: GoChi (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GoChi (120 mL/day)
Trial: 16414904
Drug: Glycolic peeling
RxNorm normalized name: orange peel extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycolic peeling and daily appliance of vitamin C
Trial: 12878618
Drug: Remifentanil 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.08 micro g kg(‐1) min(‐1)
Trial: 10762640
Drug: 5'‐DFUR (460
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'‐DFUR (460 mg/m2/day, daily, for two years)
Trial: 10762640
Drug: 5‐FU (115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU (115 mg/m2/day, daily, for two years)
Trial: 1634913
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 IV on day 1 and 5‐FU 1,000 mg/m2 per day for a 96‐hour continuous infusion repeated every 21 days
Trial: 1634913
Drug: Carboplatin 300
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 300 mg/m2 IV on day 1 and 5‐FU 1,000 mg/m2 per day for a 96‐hour continuous infusion repeated every 28 days
Trial: 1634913
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 40 mg/m2 IV given weekly
Trial: 1634913
Drug: Treatment assigned
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment assigned
Trial: 30629473
Drug: MICRO (5-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MICRO (5-min bouts of moderate-intensity physical activity performed hourly for nine consecutive hours over 4 days)
Trial: 27601419
Drug: Bromelain (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain (pooled treatments)
Trial: 1358498
Drug: Reduced glutathione
RxNorm normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced glutathione (GSH) administration (1.2 g/day and 2.4 g/day intravenously)
Trial: 1358498
Drug: Chlordiazepoxide (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (initial dose 75‐100 mg/day)
Trial: 21076721
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg atorvastatin each night (Control group)
Trial: 21076721
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg atorvastatin 12 h before PCI (Low-load group)
Trial: 21076721
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg atorvastatin 2 h to 4 h before PCI (Mid-load group)
Trial: 21076721
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg atorvastatin 2 h to 4 h before PCI (High-load group)
Trial: 12459075
Drug: Enoxaparin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.75 mg/kg) with abciximab
Trial: 12459075
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (70 U/kg) with abciximab